Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients

Patients with visceral leishmaniasis (VL)–human immunodeficiency virus (HIV) coinfection experience increased drug toxicity and treatment failure rates compared to VL patients, with more frequent VL relapse and death. In the era of VL elimination strategies, HIV coinfection is progressively becoming...

Descripción completa

Detalles Bibliográficos
Autores principales: Adriaensen, Wim, Dorlo, Thomas P. C., Vanham, Guido, Kestens, Luc, Kaye, Paul M., van Griensven, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770372/
https://www.ncbi.nlm.nih.gov/pubmed/29375567
http://dx.doi.org/10.3389/fimmu.2017.01943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770372/
https://www.ncbi.nlm.nih.gov/pubmed/29375567
http://dx.doi.org/10.3389/fimmu.2017.01943

Ejemplares similares